{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:24:57Z","timestamp":1793294697855,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaci.2025.12.1013","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:19:14Z","timestamp":1769127554000},"page":"905-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability"],"prefix":"10.1016","volume":"157","author":[{"given":"James G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Cutcutache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Skelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Rastrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S.","family":"Ferecsk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"L\u00f3pez Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Warham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.12.1013_bib1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2025.12.1013_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year","volume":"33","author":"Yasmeen","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaci.2025.12.1013_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaci.2025.12.1013_bib5","article-title":"High induction dosing of risankizumab in patients with moderate-to-severe plaque leads to marked suppression of resident memory T cell number and function in resolved psoriatic skin","volume":"191","author":"Blauvelt","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib6","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jaci.2025.02.008","article-title":"Psoriasis harbors multiple pathogenic type 17 T-cell subsets: selective modulation by risankizumab","volume":"155","author":"Kim","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/art.41652","article-title":"Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis","volume":"73","author":"Leijten","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2018.01347","article-title":"Metabolic reprogramming and longevity of tissue-resident memory T cells","volume":"9","author":"Pan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.12.1013_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib13","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","article-title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease","volume":"152","author":"Cole","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.12.1013_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.12.1013_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.12.1013_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.12.1013_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib24","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"Kim","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6500","article-title":"Developmental cell programs are co-opted in inflammatory skin disease","volume":"371","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaci.2025.12.1013_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13555-019-0310-5","article-title":"Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience","volume":"9","author":"Huang","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.12.1013_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.07.883","article-title":"50236 GUIDE trial results after withdrawal in part 3: long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms","volume":"91","author":"Sch\u00e4kel","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2025.12.1013_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.12.1013_bib30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2018.01770","article-title":"Armed and ready: transcriptional regulation of tissue-resident memory CD8 T cells","volume":"9","author":"Behr","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2009.03244.x","article-title":"Interleukin-7 promotes the survival of human CD4+ effector\/memory T cells by up-regulating Bcl-2 proteins and activating the JAK\/STAT signalling pathway","volume":"130","author":"Chetoui","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2025.12.1013_bib32","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1984","article-title":"Time to loss of response following withdrawal of ixekizumab in patients with moderate-to-severe psoriasis","volume":"102","author":"Papp","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.21617","article-title":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?","volume":"187","author":"Reich","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110328","article-title":"IL-17A\/F double producing T cells, unstable Tregs and quiescent TRMs in clinically healed lesions are potential cellular candidates for recurrence of psoriasis","volume":"266","author":"Peng","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.12.1013_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jcm12010035","article-title":"The clinical significance of simultaneous IL-17A and IL-17F blockade in psoriasis non-responding to anti-IL17A therapy","volume":"12","author":"Kokolakis","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2025.12.1013_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-025-00922-2","article-title":"Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-23 inhibitors: a multicenter retrospective study","volume":"26","author":"Sood","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib40","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/exd.14828","article-title":"Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: the ARROW study","volume":"32","author":"Krueger","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2024.06.1116","article-title":"LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial","volume":"144","author":"Chen","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.12.1013_bib43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fimmu.2018.00795","article-title":"A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it","volume":"9","author":"Tamassia","year":"2018","journal-title":"Front Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:39:25Z","timestamp":1778722765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0091674926000126"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.12.1013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.12.1013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}